Stella Pharma Corporation (TYO:4888)

Japan flag Japan · Delayed Price · Currency is JPY
317.00
-9.00 (-2.76%)
Oct 28, 2025, 2:42 PM JST
-2.76%
Market Cap11.10B
Revenue (ttm)992.00M
Net Income (ttm)-135.00M
Shares Out34.03M
EPS (ttm)-3.97
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume79,100
Average Volume425,800
Open326.00
Previous Close326.00
Day's Range316.00 - 326.00
52-Week Range281.00 - 565.00
Beta0.91
RSI37.87
Earnings DateNov 7, 2025

About Stella Pharma

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 43
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4888
Full Company Profile

Financial Performance

In 2024, Stella Pharma's revenue was 961.00 million, an increase of 257.25% compared to the previous year's 269.00 million. Losses were -140.00 million, -81.65% less than in 2023.

Financial Statements

News

There is no news available yet.